ReviewCureus2021
Osteoarthritis: A Review of Novel Treatments and Drug Targets.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Advancing osteoarthritis management: integrating new insights and addressing persistent roadblocks.Inflammopharmacology · 2025Review
- Hyaluronic acid-loaded drug-eluting nanofibrous pad for the treatment of degenerative arthritis.RSC advances · 2025Article
- Well-known polypeptides of deer antler velvet with key actives: modern pharmacological advances.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Epigenetic regulatory mechanism of ADAMTS12 expression in osteoarthritis.Molecular medicine (Cambridge, Mass.) · 2023Article
- Functional biomaterials for osteoarthritis treatment: From research to application.Smart medicine · 2022Review
- Stage related metabolic profile of the synovial fluid in patients with acute flares of knee osteoarthritis.Medicine and pharmacy reports · 2022Article
- Role of GDF15/MAPK14 Axis in Chondrocyte Senescence as a Novel Senomorphic Agent in Osteoarthritis.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis affects over 10% of our population over the age of 60 years old, significantly reducing their quality of life and increasing morbidity. A number of aetiological factors contribute to the development of osteoarthritis including obesity, genetic factors, injury and increasing age. Many of the pathological processes which underlie the condition remain poorly understood and therefore limited progress has been made in developing effective disease modifying treatments. This review article aims to summarise our current understanding of osteoarthritis, the molecular mechanisms which drive the disease and current progress in developing therapeutic strategies to target these.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.